Specialty Pharma Journal Specialty, Precision & Technology
DURHAM, N.C., April 19, 2018 (GLOBE NEWSWIRE) — Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in …
Tag Archives: argos
April, 2018
February, 2017
-
22 February
Committee Recommends that Argos Therapeutics Discontinue Late-Stage Kidney Cancer Trial for Futility
DURHAM, N.C., Feb. 22, 2017 (GLOBE NEWSWIRE) — Argos Therapeutics Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that the Independent Data Monitoring Committee (IDMC) for the company’s pivotal Phase 3 ADAPT clinical trial …
January, 2015
-
9 January
Argos’ Experimental HIV Immunotherapy Fails Phase 2 Study
Argos Therapeutics Inc.’s experimental HIV immunotherapy failed its mid-stage trial. The company announced today that its investigational fully personalized immunotherapy, AGS-004, failed to meet the primary endpoint in its Phase 2b clinical trial, evaluating the drug in patients chronically infected with HIV-1. According to top-line results, AGS-004 did not meet …